Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
CHINO HILLS, CA / ACCESS Newswire / May 2, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces Dr. Leonardo Mirandola joined the Company as Advisory Board Member. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, will spearhead the company's initiatives to advance its CAR-T cell projects toward clinical trials.
Dr. Mirandola brings a wealth of expertise in operational management, R&D, and clinical development, with a proven track record in transforming innovative scientific breakthroughs into viable treatment options. He holds a Ph.D. and a Master's degree from the University of Milano, Italy.
'Dr. Mirandola's extensive background in cell therapy and his remarkable success in clinical translation make him an invaluable addition to our team,' said David Aguilar of SOHM Inc. 'His leadership will be instrumental as we push the boundaries of CAR-T cell production and therapy and strive to bring new treatment options to those battling cancer.'
Before joining SOHM Inc., Dr. Mirandola served as Chief Scientific Officer and Interim Chief Operations Officer at Kiromic Biopharma, where he played a pivotal role in developing and overseeing clinical operations for various groundbreaking therapies. His contributions led to the advancement of an autologous dendritic cell therapeutic vaccine for solid tumors and an allogeneic gamma-delta T-cell therapy, which has received Fast-Track-designation by the FDA and showed positive results in Phase 1 trials for patients with Stage 4 non-small cell lung cancer.
Dr. Mirandola has a remarkable record of securing patents for novel manufacturing techniques and AI-driven target discovery processes, which have significantly advanced the understanding and development of cell therapies. His leadership in establishing cGMP-compliant manufacturing processes will be critical as SOHM Inc. prepares its CAR-T cell projects for rigorous clinical evaluation.
'I am excited to join SOHM Inc. and collaborate with such a talented team dedicated to making a difference in the lives of cancer patients,' said Dr. Mirandola.
SOHM, Inc. is harnessing the power of ABBIE, its proprietary gene editing platform, to accelerate and enhance the commercialization of CAR-T cell therapies. Unlike traditional viral-based or CRISPR systems, ABBIE offers a cost-efficient editing approach that significantly reduces manufacturing complexity and regulatory hurdles. By integrating ABBIE into its CAR-T development pipeline, SOHM aims to streamline production timelines, improve genetic payload fidelity, and broaden the therapeutic window - ultimately making advanced cell therapies more accessible and scalable for a wider range of cancer patients.
For further information on SOHM Inc. and its latest advancements in biotechnology, please visit www.sohm.com ( http://www.sohm.com ).
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
J.B. Poindexter & Co., Inc. Acquires Ambulance Manufacturing Leader Demers Braun Crestline Medix
HOUSTON--(BUSINESS WIRE)--J.B. Poindexter & Co., Inc. (JBPCO), a privately held North American manufacturing leader serving the commercial vehicle and specialty manufacturing industries, today announced the acquisition of Demers Braun Crestline Medix (DBCM). 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. Share Headquartered in Beloeil, Quebec (Canada), DBCM is one of North America's largest ambulance manufacturers with a strong presence across the U.S. and Canadian markets. Known for advanced innovation and paramedic-driven design, DBCM has delivered more than 70,000 units to over 40 countries and employs more than 1,500 team members across its operations. 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. 'As JBPCO celebrates its 40th anniversary, and each of the DBCM brands celebrates decades of dedication in the emergency vehicle industry, we are proud to bring together more than 500 years of combined manufacturing excellence across our portfolio of companies. DBCM has built a solid foundation, and we look forward to investing in its future, supporting the team, enhancing the products, and unlocking new opportunities for growth.' Demers recently launched its 11 th -generation ambulance platform and continues to set the bar in safety, design, and performance with paramedic-centric features like the FX Care Module. As part of JBPCO, the Company will continue to operate with brand autonomy while benefiting from expanded resources, shared capabilities, and a culture that values team member contributions. 'Joining JBPCO is a major milestone for our organization and our team,' said Alain Brunelle, CEO of Demers Braun Crestline Medix. 'We are united by a mission to improve lives, one relationship and one vehicle at a time—and this partnership ensures we can continue doing just that, with even greater scale and support.' JBPCO's total revenue will reach $3 billion with this acquisition, reinforcing its role as a cornerstone in the commercial and specialty vehicle manufacturing space—from last-mile delivery and work trucks to emergency response vehicles. About J.B. Poindexter & Co., Inc. J.B. Poindexter & Co., Inc. (JBPCO) is a privately held, diversified manufacturing company providing best-in-class commercial automotive and industrial solutions. JBPCO owns and operates a portfolio of leading business units including Morgan Truck Body, LLC; Morgan Olson, LLC; The Reading Truck Group, LLC; Truck Accessories Group, LLC d/b/a LEER Group; Masterack, LLC; EFP, LLC; Federal Eagle, LLC; and EAVX. JBPCO is headquartered in Houston, Texas and with the acquisition of DBCM, now employs more than 10,000 team members across North America. For more information, visit or connect on LinkedIn. Demers Braun Crestline Medix is one of North America's largest ambulance manufacturers, with a legacy of over 175 years across its four leading brands. Headquartered in Beloeil, Quebec, and operating in both Canada and the United States, the company designs and manufactures ambulances that meet the evolving needs of emergency service providers. Its brands—Demers, Braun, Crestline, and Medix—have delivered over 70,000 units in more than 40 countries. To learn more, visit and
Business Upturn
9 hours ago
- Business Upturn
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc. , No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Yahoo
9 hours ago
- Yahoo
Lumen (LUMN) Subsidiary to Raise $1B for AI-Focused Debt Refinancing
Lumen Technologies, Inc. (NYSE:LUMN) is one of the 11 must-buy AI stocks analysts are betting on. On June 16, the company announced its wholly owned subsidiary Level 3 Financing plans to raise $1 billion in the market to refinance debt. An aerial view of a communications satellite in orbit, beaming its signal down to Earth. Level 3 will offer a $1 billion aggregate principal of First Lien Notes due in 2033. The unit will leverage net proceeds from the offering to redeem all $924.522 million in aggregate principal amount of senior secured notes due in 2030. The refinancing move extends the maturity date of Level 3 financing debt from 2030 to 2033. Lumen Technologies, Inc. (NYSE:LUMN) is a global communications and IT services company that offers solutions that help businesses connect people's data and applications securely. Its solutions also help companies realize artificial intelligence potential through its metro connectivity edge cloud and managed service capabilities. While we acknowledge the potential of LUMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Healthcare Stocks to Buy Now and 10 Stocks Analysts Are Upgrading Today. Disclosure: None. Sign in to access your portfolio
